20

HEALTH OF WOMAN. 2016.10(116):69–75; doi 10.15574/HW.2016.116.69 
 

Experience of drug treatment benign prostatic glands with sexual disorders

Gurzhenko Y. M., Kvach M. D.

National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev

The paper shows the experience of drug treatment therapy according to the standards of the European Association of Urology patients with benign prostatic hyperplasia sexual disorders. Results of treatment was evaluated based on changes in symptoms of lower urinary department, objective information about its functional status after 3, 6 and 12 months. Also studied the dynamics of sexual disorders and emotional state was assessed at 1, 3, 6 and 12 months. The majority of positive results was achieved by 6 months after starting treatment.

Key words: benign prostatic hyperplasia, sexual disorders, medication.

REFERENCES

1. Kolesnik NA, Nepomnyaschiy VN, Samuseva ES. 2006. Teoriya i praktika dokazatelnoy meditsinyi. K, Poligrafplyus:200.

2. Pasechnikov SP. 2015. Printsipi klasifikatsiyi. Diagnostika ta likuvannya dobroyakisnoyi giperplaziyi peredmihurovoyi zalozi. Med. aspekty zdorovya muzhchiny 4(19):5–10.

3. Traysh AM, Kim NN, Goldsteyn I. 2008. Testosteron i erektilnaya disfunktsiya: ot fundamentalnih issledovaniy k novoy klinicheskoy paradigme lecheniya muzhchin s vozrastnyim androgennyim defitsitom i erektilnoy disfunktsiey. Zdorove muzhchiny 1:24–36

4. European Association of Urology. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. 2015: 21.

5. Giuliano F et al. 2013. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur. Urol. 63:506–616. https://doi.org/10.1016/j.eururo.2012.09.006; PMid:23018163

6. Rosen RC, Altwein J, Boyl P et al. 2003. Lower urinary tract symptoms and male sexual dysfunction: the Multi-National surgery of the ageing male (MSAM-7). Eur. Urol. 44:637–649. https://doi.org/10.1016/j.eururo.2003.08.015; PMid:14644114

7. Seki N, Naito S, Oshima S. 2003. Prevalence and preference with regard to various surgical treatment for benign prostatic hypertrophy: a survey for the Japanese endourology and ESWL society member. Nippon Hinyokika Gakkai Zasshi 94; 4: 495–502. https://doi.org/10.5980/jpnjurol1989.94.495

8. Donatucci CF, Brock GB, Goldfischer ER et al. 2011. Tabalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 107(7):1110–6. https://doi.org/10.1111/j.1464-410X.2010.09687.x; PMid:21244606

9. Green R, Hicks RW. 2011. Orally disintegrating vardenafil tablets for the treatment of erectile dysfunction: efficacy, safety, and patient acceptability. Patient Prefer Adherence. 5:181–185. https://doi.org/10.2147/PPA.S14030; PMid:21573049 PMCid:PMC3090379

10. Nishikawa G, Ikawab K, Nakamura K et al. 2013. Prostatic penetration of meropenem гhumans, and dosage considerations hiprostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation. Int. J. Antimicrobial Agents. 41:267–271. https://doi.org/10.1016/j.ijantimicag.2012.11.001; PMid:23313536

11. Shabsigh R. 2004. Testosterone therapy in erectile dysfunction. Aging Male. 7:312–318. https://doi.org/10.1080/13685530400016540; PMid:15799127